全文获取类型
收费全文 | 42606篇 |
免费 | 2618篇 |
国内免费 | 783篇 |
专业分类
耳鼻咽喉 | 182篇 |
儿科学 | 781篇 |
妇产科学 | 566篇 |
基础医学 | 5332篇 |
口腔科学 | 265篇 |
临床医学 | 3590篇 |
内科学 | 5811篇 |
皮肤病学 | 724篇 |
神经病学 | 1987篇 |
特种医学 | 588篇 |
外国民族医学 | 1篇 |
外科学 | 2408篇 |
综合类 | 4682篇 |
预防医学 | 4476篇 |
眼科学 | 260篇 |
药学 | 10990篇 |
12篇 | |
中国医学 | 631篇 |
肿瘤学 | 2721篇 |
出版年
2023年 | 495篇 |
2022年 | 936篇 |
2021年 | 1318篇 |
2020年 | 1156篇 |
2019年 | 1074篇 |
2018年 | 1129篇 |
2017年 | 1123篇 |
2016年 | 1152篇 |
2015年 | 1294篇 |
2014年 | 2756篇 |
2013年 | 3592篇 |
2012年 | 2576篇 |
2011年 | 2945篇 |
2010年 | 2178篇 |
2009年 | 2121篇 |
2008年 | 2154篇 |
2007年 | 1995篇 |
2006年 | 1698篇 |
2005年 | 1474篇 |
2004年 | 1242篇 |
2003年 | 1052篇 |
2002年 | 854篇 |
2001年 | 778篇 |
2000年 | 722篇 |
1999年 | 716篇 |
1998年 | 489篇 |
1997年 | 502篇 |
1996年 | 503篇 |
1995年 | 499篇 |
1994年 | 544篇 |
1993年 | 413篇 |
1992年 | 456篇 |
1991年 | 426篇 |
1990年 | 363篇 |
1989年 | 311篇 |
1988年 | 349篇 |
1987年 | 294篇 |
1986年 | 282篇 |
1985年 | 381篇 |
1984年 | 352篇 |
1983年 | 209篇 |
1982年 | 230篇 |
1981年 | 113篇 |
1980年 | 136篇 |
1979年 | 84篇 |
1978年 | 87篇 |
1977年 | 87篇 |
1976年 | 78篇 |
1975年 | 69篇 |
1974年 | 51篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
31.
32.
33.
34.
35.
BackgroundBisphosphonates and monoclonal antibodies are drugs primarily developed to inhibit osteoclast-mediated bone resorption and are used to treat an array of skeletal pathologies. Their use is aimed at increasing bone health and therefore reducing fracture risks. The aim of this study was to evaluate the effectiveness of bone protection therapy on improving bone mineral density (BMD) in patients following a fracture.MethodsInclusion criteria consisted of patients who sustained a skeletal fracture and were subsequently commenced on bone protection therapy. Dual-energy X-ray Absorptiometry (DEXA) scans were performed at baseline and following a consented period of drug therapy. Bone health data included T-Scores, Z-Scores, FRAX Major, FRAX Hip and BMD. The clinical effectiveness of four bisphosphonates (alendronate, risedronate, pamidronate and zoledronate) and one monoclonal antibody (denosumab) were evaluated.ResultsA total of 100 patients were included in the study. Overall, bone protection therapy significantly improved Z-score Hip, Z-score Spine, T-score Spine and BMD Spine (p < 0.05). There was a marked difference between drug therapies. Denosumab and zoledronate were associated with the greatest treatment effect size. Alendronate only improved Z-score Spine and Z-score Hip (p < 0.05). Pamidronate and risedronate did not demonstrate any statistically significant improvement across any DEXA parameter.ConclusionOverall, bisphosphonates/monoclonal antibodies confer beneficial effects on bone health as measured by DEXA scans in patients following skeletal fractures. However, the magnitude of improvement varies among the commonly used drugs. Alendronate, zoledronate and denosumab were associated with greatest therapeutic benefit. Bone protection therapy did not improve fracture risk of patients (FRAX scores). 相似文献
36.
《JACC: Cardiovascular Interventions》2022,15(7):741-750
ObjectivesThe aim of this study was to report 1-year clinical outcomes following commercial transcatheter left atrial appendage occlusion (LAAO) in the United States.BackgroundThe National Cardiovascular Data Registry LAAO Registry was initiated to meet a condition of Medicare coverage and allow the assessment of clinical outcomes. The 1-year rates of thromboembolic events after transcatheter LAAO in such a large cohort of “real-world” patients have not been previously reported.MethodsPatients entered into the National Cardiovascular Data Registry LAAO Registry for a Watchman procedure between January 1, 2016, and December 31, 2018, were included. The primary endpoint was ischemic stroke. Key secondary endpoints included the rate of ischemic stroke or systemic embolism, mortality, and major bleeding. Major bleeding was defined as any bleeding requiring hospitalization, and/or causing a decrease in hemoglobin level > 2g/dL, and/or requiring blood transfusion that was not hemorrhagic stroke. The Kaplan-Meier method was used for 1-year estimates of cumulative event rates.ResultsThe study population consisted of 36,681 patients. The mean age was 76.0 ± 8.1 years, the mean CHA2DS2-VASc score was 4.8 ± 1.5, and the mean HAS-BLED score was 3.0 ± 1.1. Prior stroke was present in 25.5%, clinically relevant bleeding in 69.5%, and intracranial bleeding in 11.9%. Median follow-up was 374 days (IQR: 212-425 days). The Kaplan-Meier–estimated 1-year rate of ischemic stroke was 1.53% (95% CI: 1.39%-1.69%), the rate of ischemic stroke or systemic embolism was 2.19% (95% CI: 2.01%-2.38%), and the rate of mortality was 8.52% (95% CI: 8.19%-8.87%). The 1-year estimated rate of major bleeding was 6.93% (95% CI: 6.65%-7.21%). Most bleeding events occurred between discharge and 45 days following the procedure.ConclusionsThis study characterizes important outcomes in a national cohort of patients undergoing transcatheter LAAO in the United States. Clinicians and patients can integrate these data in shared decision making when considering this therapy. 相似文献
37.
美国食品药品管理局(FDA)于2022年7月发布了"治疗等效性评价供企业用指导原则"(草案)。该指导原则阐明了FDA治疗等效性的标准以及治疗等效性编码系统,目的是准确评价仿制药与参比制剂的治疗等效性并通过治疗等效性代码,在"橙皮书"中迅速检索到治疗等效的仿制药。而中国目前尚无类似的指导原则,详细介绍FDA该指导原则主要内容,期望对中国加强仿制药的治疗等效性评价和加速完善和实施符合国情的治疗等效性编码系统有所帮助。 相似文献
38.
39.
40.
Dabigatran etexilate (DABE), an oral anticoagulant prodrug, is nearly completely metabolized to the dabigatran (DAB) active metabolite by carboxylesterase-1 (CES1) and carboxylesterase-2 (CES2). The high interpatient variation in DAB plasma concentrations, coupled with its low therapeutic index, emphasizes the need to understand how CES1 and CES2 impact active metabolite formation. Previous work focused on CES1 enzyme activity but the contributions of CES2 remain unclear. The purpose of this study was to determine how CES2 activity influences DAB active metabolite formation. We compared the efficiency of DAB formation from DABE when exposed sequentially to human intestinal and then human hepatic microsomes (mimicking the normal metabolic sequence) with the reverse metabolic sequence in which DABE is exposed to hepatic and then intestinal microsomes. The poor efficiency of DAB formation with reverse sequential hydrolysis indicates that CES2 activity is crucial for active metabolite formation. Thus, the decrease in DAB formation with normal sequential hydrolysis was more sensitive to CES2 inhibition by verapamil (CES2 IC50 = 3.4 μM) than CES1 inhibition by diltiazem (CES2 IC50 = 9.1 μM). These results show CES2 activity plays a crucial role in DAB formation and that variability in its activity is an important determinant of therapeutic response. 相似文献